BioSpace News Archive

ImmuneBridge today announced the close of an oversubscribed $12 million seed financing co-led by global investors Insight Partners and M Ventures, the strategic, corporate venture capital arm of Merck KGaA, Darmstadt, Germany.

Akebia Therapeutics, Inc. announced that it adjourned, without conducting any business, the special meeting of stockholders on Tuesday, April 11, 2023 to allow the company to solicit from its stockholders the additional proxies necessary to obtain approval of the proposals described in the company’s revised definitive proxy statement filed with the Securities and Exchange Commission on March 17, 2023.

FUJIFILM Irvine Scientific, Inc. announced the expansion of its BalanCD CHO Media Platform portfolio with the addition of two new, chemically defined growth media- BalanCD CHO Perfusion and BalanCD CHO DG44.

MaaT Pharma announced that promising clinical data for its drug candidates, MaaT013 and MaaT033 will be reported in two oral presentations by Pr. Florent Malard, Professor of Hematology at the Saint-Antoine Hospital and Sorbonne University during the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2023).

Aitia, announced today that data from its Multiple Myeloma Digital Twin model will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting being held from April 14-19 in Orlando, Florida.

Merck, known as MSD outside of the United States and Canada, has earned a place on the Fortune 100 Best Companies to Work For list for the second time in the past three years.

A first-of-its-kind study has established pediatric reference intervals for two common tests for cardiovascular disease. Published in AACC’s The Journal of Applied Laboratory Medicine, these findings are crucial to advancing diagnosis and treatment of heart conditions in children.

Nurix Therapeutics, Inc. (Nasdaq: NRIX), today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Thursday, April 20 at 3:00 p.m. ET.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head of Research, is scheduled to participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, at 12:00 p.m. PT / 3:00 p.m. ET.

Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced financial results for the year ended December 31, 2022 and recent corporate highlights.